article · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences
Nosocomial infections are one of the most common medical complications affecting patients admitted to the intensive care units (ICUs). This study aimed to investigate the multidrug-resistance (MDR), metallo-β-lactamases (MBLs) production in imipenem resistant (IR) species, detection of biofilm, and molecular characterization of MDR-associated genes in A. baumannii (AB) isolated from ICUs in Egypt. A total 77 (25.08%) A. baumannii isolates were recovered from 307 Gram negative bacteria (GNB) collected from different clinical specimens of infected cases hospitalized at SICU, MICU, CCU, NICU and PICU in 4 different Egyptian Hospitals. MDR were observed in 55/77 isolates out of them, 33 isolates were meropenem resistant (MR), while 35 isolates were imipenem resistant (IR). Out of 35 IRAB 19 isolates were MBL producers by CDT while 25 isolates were MBL producers by DDST. Strong biofilm production was observed in (20/33 isolates) of MRAB. All A. baumannii strains involved in this study produced the expected band of 353 bp, for blaOXA-51-like gene. Among the 19 CDT-positive A. baumannii isolates, 11 (57.9%) isolates were detected MBL encoding gene (blaNDM) and 18/23 (78.3%) of tested isolates were positive for adeB gene. This study revealed that MDR A. baumannii strains accommodate blaOXA-51, blaNDM and adeB genes were widely circulating in ICUs of Egyptian hospitals. In addition, the MDR biofilm and MBL production were observed among A. baumannii isolates that represents a serious public health problem.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/rpbs.2024.326722.1329
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.